Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 15,235

Document Document Title
WO/2017/091837A3
A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B. Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among...  
WO/2017/175064A1
A method for the bio-enzymatic synthesis of tetrahydrocannabivarin (THC-v), cannabivarin (CBV) and cannabinol (CBN) by contacting a compound according to Formula I with a cannabinoid synthase enzyme. The cannabinoids are produced in the ...  
WO/2017/177004A1
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...  
WO/2017/156520A1
Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-V as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.  
WO/2017/152539A1
Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicy...  
WO/2017/146400A1
The present invention relates to a compound for detecting phosgene and DCP (diethyl chlorophosphate) and a composition for detecting phosgene and DCP (diethyl chlorophosphate) comprising the said compound. More precisely, the compound fo...  
WO/2017/146466A1
The present specification relates to a heterocyclic compound and an organic light emitting element comprising the same.  
WO/2017/139962A1
A method for extracting herbacetin from rhodiola rosea comprises the steps of: 1) extracting a medicinal material by using an extraction solvent, and then concentrating to obtain an extract paste; 2) extracting the extract paste, and aci...  
WO/2017/135286A1
Provided are an urolithins-containing aqueous solution comprising urolithins and collagen, a dried solid composition thereof, and a production method therefor, and an urolithins stabilizing method.  
WO/2017/132775A1
This invention provides novel compositions and methods for the treatment of leiomyoma. In some other aspects, this invention provides novel compositions and methods comprising prodrugs of (-)-epigallocatechin-3-gallate (EGCG) and prodrug...  
WO/2017/131047A1
The presentt invention addresses the problem of providing a photocuring method that obtains a crosslinked product (resin) quickly and efficiently, a compound used in the photocuring method, and a photocurable resin composition containing...  
WO/2017/125900A1
The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl) chromans of formula I. The intermediates thus obtained can ...  
WO/2017/125638A1
The invention relates to a method for the fluorescence-based determination of tertiary amines by means of reactants that use halogenated-xanthene-based dyes. The invention also relates to a kit comprising the reactants necessary for carr...  
WO/2017/124949A1
The present invention relates to flavanone derivatives and a preparation method and use thereof, and in particular relates to the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composi...  
WO/2017/121855A1
The present invention relates to compounds of formula (I) These compounds are useful in the treatment of many diseases such as a skin disease, an allergy, an autoimmune disease, a cardiovascular disease, a lung disease, asthma, a bacteri...  
WO/2017/122722A1
The present invention provides: a compound represented by formula (1) as a pharmaceutical agent which is useful as a neuroregeneration promoting agent [in the formula, R1-L- represents R1-OC(O)-, etc., R1 represents a hydrogen atom, an o...  
WO/2017/120591A1
The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhi...  
WO/2017/113013A1
The present disclosure provides biophotonic topical compositions, kits and their uses. In some aspects, the biophotonic topical compositions of the present disclosure comprise a first chromophore, a salt selected from one or more bicarbo...  
WO/2017/111387A1
The present invention relates to a pseudo-ceramide compound and a preparation method therefor. The pseudo-ceramide compound of the present invention can provide an antioxidative effect, and can exhibit improved physical properties, such ...  
WO/2017/111076A1
The invention provides an α,β unsaturated amide compound having anticancer activity shown by formula (I) or a pharmaceutically acceptable salt or the like thereof: [in the formula, A represents an optionally substituted heterocyclic di...  
WO/2017/100882A1
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and optionally a cell lysis agent. Also disclosed are methods for preparing ...  
WO/2017/106786A1
Provided herein are methods for making an alpha-tocotrienol enriched tocol mixture, such as from a plant or plant-derived material. Also provided herein are simulated moving bed purification methods for tocotrienol compounds such as alph...  
WO/2017/103840A1
The embodiments herein provides method for synthesizing water soluble forskolin 10% w/w. 250 litres of distilled water, 5 kg of pre-treated forskolin (98% w/w) and 20 kg of synthetic water soluble polymer are added into the reactor to ob...  
WO/2017/103931A1
Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and...  
WO/2017/106649A1
This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.  
WO/2017/105041A1
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used for an organic material layer of an organic electroluminescent device...  
WO/2017/106074A1
Provided are methods of treating neonatal and young non-human animals, particularly pre-weaned animals, suffering from diarrhea, and/or symptoms thereof, by administering to an animal in need thereof a proanthocyanidin polymer compositio...  
WO/2017/100869A1
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and, optionally a cell lysis agent. Also disclosed are methods for preparing...  
WO/2017/103295A1
The invention relates to coumarins of formula (I), polyols and polyurethanes produced from said coumarin, as well as the method for producing said polyurethanes, the use thereof in the preparation of coating films and method thereof for ...  
WO/2017/097752A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E2, of flocoumafen, said enantiomer E2 having, as determined by the chromatographic analysis of a flocoumafen composition comprising four configurational ...  
WO/2017/097750A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E4, of flocoumafen, said enantiomer E4 having, as determined by the chromatographic analysis of flocoumafen comprising four configurational stereoisomers ...  
WO/2017/097755A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E4, of bromadiolone, having, as determined by the chromatographic analysis carried out under conditions described hereinafter, a retention time t4 with a ...  
WO/2017/097751A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E3, of flocoumafen, said enantiomer E3 having, as determined by the chromatographic analysis of the flocoumafen, carried out under specific conditions, a ...  
WO/2017/097754A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E1, of bromadiolone, having, as determined by the chromatographic analysis of bromadiolone comprising four configurational stereoisomers of bromadiolone, ...  
WO/2017/098048A1
The present invention is directed to a process for the manufacture of 6,10, 14- trimethylpentadecan-2-one ("C18-ketone") comprising the step of hydrogenating a mixture of (5E,9E)-farnesylacetone and (5Z,9E)- farnesylacetone with hydrogen...  
WO/2017/097756A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E3, of bromadiolone, having, as determined by the chromatographic analysis of a bromadiolone composition comprising four configurational stereoisomers of ...  
WO/2017/098049A1
The present invention is directed to a process for the manufacture of 6,10,14- trimethylpentadecan-2-one ("C18-ketone") comprising the step of hydrogenating a mixture of (5E, 9E)-farnesylacetone and (5Z, 9E)- farnesylacetone with hydroge...  
WO/2017/098050A1
The present invention is directed to a process for the manufacture of 6,10,14-trimethylpentadecan-2-one ("C18-ketone") comprising the step of hydrogenating a mixture of (3E,5E,9E)-3,4-dehydrofarnesylacetone and (3Z,5E,9E)-3,4-dehydrofarn...  
WO/2017/097749A1
The invention relates to a configurational stereoisomer, referred to as enantiomer E1, of flocoumafen, said enantiomer E1 having, as determined by the chromatographic analysis of the flocoumafen, carried out under specific conditions, a ...  
WO/2017/097753A1
The invention relates to a composition comprising flocoumafen and an amount of a configurational stereoisomer, referred to as enantiomer E4, of flocoumafen, such that the ratio of this amount to the amount of flocoumafen in the compositi...  
WO/2017/094838A1
By using a fluorescent ligand for a retinoid X receptor (RXR), said ligand being indicated by one of the following formulas (1)-(3), an evaluative test of ability to bind with RXR can be easily performed. (In the formulas, R1 is methyl, ...  
WO/2017/092230A1
Provided in the present invention is a compound having the structure of formula I or a pharmaceutically acceptable salt thereof. Also provided in the present invention is a pharmaceutical composition containing the compound, and a use of...  
WO/2017/093749A1
There is described a method of preparing a compound of formula I, and optical isomers thereof: in which R1 is hydrogen or a protecting group; said method comprising oxidising verbenone and optical isomers thereof.  
WO/2017/091175A2
The present invention is related to a sun funnel (1) which enables obtaining more intense, focused sun beams on desired area by reflecting sun beams at preferred amounts which comprises; - at least an inlet (2) through which sun beams en...  
WO/2017/085720A1
Color conversion films for a LCD (liquid crystal display) having RGB (red, green, blue) color filters, as well as such displays, formulations, precursors and methods are provided, which improve display performances with respect to color ...  
WO/2017/087962A1
The invention is directed to a method of treating Alzheimer's Disease by administering to a subject in need thereof a therapeutically effective amount of cromolyn and optionally ibuprofen. The cromolyn may be in the form of cromolyn sodi...  
WO/2017/087835A1
Disclosed are bruceolides for the treatment of cancer, and other diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e...  
WO/2017/082430A1
Provided are a method for purifying fluorescein sodium, a method for producing substantially organic-solvent-free fluorescein sodium or high-purity fluorescein sodium, substantially organic-solvent-free fluorescein sodium or high-purity ...  
WO/2017/076169A1
The present invention provides a baicalein caffeine eutectic crystal, a preparation method therefor, a pharmaceutical composition, and application thereof. The baicalein caffeine eutectic crystal of the present invention has an excellent...  
WO/2017/075715A1
Disclosed are methods of favouring epithelial wound healing in a subject. Wounds suitable for this method include wounds located on the skin or in a cornea The methods comprise contacting a wound with an activator of an AKT pathway and/o...  

Matches 601 - 650 out of 15,235